Business
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population New data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settings Bas
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population ","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"New data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settings","length":165,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":495,"olType":false},{"type":"text","content":"Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025).","length":205,"tagName":"p"},{"type":"text","content":"“We look forward to sharing new clinical data that underscores how we are reimagining treatment for breast and prostate cancer, advancing highly effective therapies designed to improve quality of life, enable more personalized care and ultimately provide more time for cancer patients,” said Dushen Chetty, PhD, Global Head of Oncology Development, Novartis, Ad Interim. “Our ambition is to set new standards of care in some of the most prevalent cancers by pioneering novel technologies like radioligand therapy.”","length":514,"tagName":"p"},{"type":"text","content":"Key highlights of data accepted by ESMO include: ","length":48,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:20%;width:20%;min-width:20%;vertical-align:middle;text-align:left;padding-left:10....